Non-segmental Vitiligo clinical trials at UCSF

• Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

  Sorry, in progress, not accepting new patients

  The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).

  San Francisco, California and other locations

Last updated: November 10, 2020